Ceribell Announces FedRAMP High Authorization, Expanding Approval For Its AI-Powered Point-Of-Care EEG Across Federal Healthcare Systems

Author: Benzinga Newsdesk | April 30, 2025 08:02am

Ceribell is one of only 51 companies in the U.S. to achieve FedRAMP High authorization

Ceribell's breakthrough technology can now be deployed in federal healthcare facilities, including U.S. Department of Veterans Affairs hospitals, helping clinicians deliver faster diagnosis and treatment for patients at risk of non-convulsive seizures

CeriBell, Inc. (NASDAQ:CBLL) ("Ceribell"), a medical technology company transforming the diagnosis and management of patients with serious neurological conditions, announced today that its point-of-care electroencephalogram (EEG) system has received full FedRAMP® (Federal Risk and Authorization Management Program) High authorization from the U.S. government. This elite cybersecurity authorization is awarded to organizations that meet the government's highest security requirements. Ceribell's secure, cloud-based solution can now be adopted across federal healthcare systems, expanding access to rapid diagnosis of non-convulsive seizures for U.S. veterans and other high-risk patients. As of April 28, 2025, only 51 companies in the U.S. have achieved High authorization, and there are no other medical device companies on that list.

Designed for rapid setup and continuous brain monitoring, the Ceribell system is already in use at hospitals within the Department of Veterans Affairs (VA) after receiving Authority to Operate (ATO) in 2024. Now, FedRAMP High authorization paves the way for broader implementation throughout federal healthcare agencies, including the entire VA system, enabling more efficient deployment and secure data sharing between facilities. Achievement of this designation further establishes Ceribell as a trusted partner to health systems and validates its commitment to securing patient data while enhancing patient care.

Posted In: CBLL